123 related articles for article (PubMed ID: 9873863)
1. A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. II. Improvements of CD4/CD8 ratio after treatments with heat-inactivated factor concentrates.
Shen MC; Hu FC; Lin JS; Tsai W; Fon MF; Wang EC
Haemophilia; 1998 Jan; 4(1):33-40. PubMed ID: 9873863
[TBL] [Abstract][Full Text] [Related]
2. A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. I. Immunological associations with the consumption of factor concentrates.
Ming-Ching S; Fuei-Yuen L; Yen-Ping K; Ron-Fon H
Haemophilia; 1995 Oct; 1(4):243-8. PubMed ID: 27214631
[TBL] [Abstract][Full Text] [Related]
3. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
[TBL] [Abstract][Full Text] [Related]
4. Replacement therapy with plasma-derived factor VIII concentrates induces skew in T-cell receptor usage and clonal expansion of CD8+ T-cell in HIV-seronegative hemophilia patients.
Matsutani T; Sakurai Y; Yoshioka T; Tsuruta Y; Suzuki R; Shima M; Yoshioka A
Thromb Haemost; 2003 Aug; 90(2):279-92. PubMed ID: 12888876
[TBL] [Abstract][Full Text] [Related]
5. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
Teitel JM; Card R; Strawczynski H
Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
[TBL] [Abstract][Full Text] [Related]
6. Changes in T4/T8 ratio over a ten years period related to the factor VIII concentrates used in a group of HIV negative haemophiliacs.
Smid WM; van der Meer J; Halie MR
Thromb Haemost; 1995 Mar; 73(3):552-3. PubMed ID: 7667844
[No Abstract] [Full Text] [Related]
7. The choice of plasma-derived clotting factor concentrates.
Mannucci PM
Baillieres Clin Haematol; 1996 Jun; 9(2):273-90. PubMed ID: 8800505
[TBL] [Abstract][Full Text] [Related]
8. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y).
Evans JA; Pasi KJ; Williams MD; Hill FG
Br J Haematol; 1991 Nov; 79(3):457-61. PubMed ID: 1751373
[TBL] [Abstract][Full Text] [Related]
9. Clotting factors isolated with monoclonal antibodies.
Gomperts ED
Curr Stud Hematol Blood Transfus; 1991; (58):52-8. PubMed ID: 1954774
[No Abstract] [Full Text] [Related]
10. Immunological effects of intermediate purity clotting factor concentrates: failure to affect lymphocyte activation in vivo.
Higgins JA; Giangrande PL; Kernoff PB; Goodall AH
Br J Haematol; 1993 Feb; 83(2):296-305. PubMed ID: 8457478
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?
Eichinger S; Pabinger I; Kyrle PA; Köller U; Kier P; Schneider B; Lechner K
Haemostasis; 1992; 22(1):25-31. PubMed ID: 1521824
[TBL] [Abstract][Full Text] [Related]
12. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
[TBL] [Abstract][Full Text] [Related]
13. [The effect of the type of factor VIII concentrate on the CD4 lymphocyte count in hemophiliacs with human immunodeficiency virus infection: the results of a meta-analysis].
Montoro Ronsano JB; Oliveras Martín J; Tusell Puigbert JM
Med Clin (Barc); 1994 Nov; 103(18):690-4. PubMed ID: 7808075
[TBL] [Abstract][Full Text] [Related]
14. GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates.
Woelfle J; Berg T; Bialek R; Keller KM; Effenberger W; Wagner N
Arch Dis Child; 1999 May; 80(5):429-32. PubMed ID: 10208947
[TBL] [Abstract][Full Text] [Related]
15. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
[TBL] [Abstract][Full Text] [Related]
16. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
[TBL] [Abstract][Full Text] [Related]
17. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
Funk M; Ebener U; Kreuz W; Ehrenforth S
Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
[No Abstract] [Full Text] [Related]
18. The role of HIV infectivity and composition of factor VIII concentrates on the immunity of haemophiliacs positive for HIV antibodies.
Allain JP; Frommel D; Bosser C; Gazengel C; Larrieu MJ; Sultan Y
Vox Sang; 1987; 53(1):37-43. PubMed ID: 3116770
[TBL] [Abstract][Full Text] [Related]
19. Infusion of clotting factor concentrates in haemophilia.
Gomperts ED
Br J Haematol; 1992 Aug; 81(4):625. PubMed ID: 1390258
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs.
Smid WM; van der Meer J; Halie MR
Haemostasis; 1995; 25(5):229-36. PubMed ID: 7489961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
